2018年药品集采政策推行后,很多依赖仿制药收入的传统药企,利润在一夜之间锐减。面对这种形势,企业们纷纷吹响向创新药企转型号角。 现如今,药企的转型初见成效。近日,多家药企公布的2025年半年报显示,创新药已撑起了公司一半以上的收入。 创新药成业绩增长点 恒瑞医药(600276.SH、01276.HK)公布的半年报显示,2025年上半年,公司实现营业收入157.62亿元,同比增长15.88%...
Source Link2018年药品集采政策推行后,很多依赖仿制药收入的传统药企,利润在一夜之间锐减。面对这种形势,企业们纷纷吹响向创新药企转型号角。 现如今,药企的转型初见成效。近日,多家药企公布的2025年半年报显示,创新药已撑起了公司一半以上的收入。 创新药成业绩增长点 恒瑞医药(600276.SH、01276.HK)公布的半年报显示,2025年上半年,公司实现营业收入157.62亿元,同比增长15.88%...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.